KCM
ALXN

Kingdon Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Kingdon Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-50,000
Closed -$6.96M – 138
2016
Q1 		$6.96M Buy
+50,000
New +$7.34M 0.38% 63

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kingdon Capital Management's ALXN Position: Q3 2020 in Review

Kingdon Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 135,500 shares — an estimated $15.2M sold.

Kingdon Capital Management first reported a position in ALXN in Q4 2016 and held it in 3 quarters. The position peaked at $15.2M in Q2 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Kingdon Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Kingdon Capital Management sold 135,500 Alexion Pharmaceuticals shares in Q3 2020, an estimated $15.2M.
  • Kingdon Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Kingdon Capital Management's Alexion Pharmaceuticals position peaked at $15.2M in Q2 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Kingdon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.